research use only

4-PBA (Sodium Phenylbutyrate) HDAC inhibitor

Name: 4-PBA (Sodium Phenylbutyrate)
Brand: Selleck Chemicals
SKU: S4125
Availability: InStock
Rating: 5 (21 reviews)

Cat.No.S4125

4-PBA (Sodium Phenylbutyrate) is a salt of 4-phenylbutyrate or 4-phenylbutyric acid. This compound is a histone deacetylase inhibitor, used to treat urea cycle disorders.

Chemical Structure

Molecular Weight: 187.19

Jump to Mechanism of Action Cell Culture & Working Concentration Solubility Chemical Information, Storage & Stability Specificity

Quality Control

Batch: Purity: 99.99%

99.99

Related Targets	DNA/RNA Synthesis Topoisomerase PPAR PARP Sirtuin ATM/ATR Casein Kinase eIF MDM DNA-PK DHFR Nucleoside Analog/Antimetabolite DNA alkylator Telomerase Thymidylate Synthase CRISPR/Cas9 RAD51 BMI-1 LIM kinase RNR Alkylating Agent NUDIX G-quadruplex High-mobility Group OGG1 MTH1 SMN FENs WRN Pax
Related Products	Entinostat (MS-275) TSA (Trichostatin A) Mocetinostat (MGCD0103) RGFP966 Tubastatin A Ricolinostat (ACY-1215) Quisinostat (JNJ-26481585) Dihydrochloride MC1568 Tubastatin A HCl PCI-34051 Tacedinaline (CI994) LMK-235 Fimepinostat (CUDC-907) Tubacin Givinostat (ITF-2357) Hydrochloride Monohydrate TMP269 AR-42 Sodium butyrate Pracinostat (SB939) Santacruzamate A (CAY10683) Abexinostat (PCI-24781) (-)-Parthenolide CUDC-101 Dacinostat (LAQ824) CAY10603 RG2833 (RGFP109) Tasquinimod Tucidinostat (Chidamide) TMP195 Nexturastat A

Cell Culture, Treatment & Working Concentration

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
Hela	Function assay			Inhibition of HDAC in human Hela cells nuclear extracts by fluorimetric assay, Ki=6.34μM	19520580
U937	Function assay	4 mM	8 to 48 hrs	Induction of CAMP mRNA expression in human U937 cells at 4 mM after 8 to 48 hrs by RT-PCR analysis	19770273
VA10	Function assay	4 mM	24 hrs	Induction of CAMP mRNA expression in human VA10 cells at 4 mM after 24 hrs by RT-PCR analysis	19770273
HT-29	Function assay	4 mM	8 to 48 hrs	Induction of CAMP mRNA expression in human HT-29 cells at 4 mM after 8 to 48 hrs by RT-PCR analysis	19770273
A498	Function assay	4 mM	8 to 48 hrs	Induction of CAMP mRNA expression in human A498 cells at 4 mM after 8 to 48 hrs by RT-PCR analysis	19770273
VA10	Function assay	4 mM	24 hrs	Induction of DEFB1 mRNA expression in human VA10 cells at 4 mM after 24 hrs by RT-PCR analysis	19770273
VA10	Function assay	4 mM	24 hrs	Induction of LL-37 protein expression in human VA10 cells at 4 mM after 24 hrs by Western blotting	19770273
VA10	Function assay	20 nM	24 hrs	Induction of LL-37 protein expression in human VA10 cells at 20 nM after 24 hrs by Western blotting	19770273
Click to View More Cell Line Experimental Data

Chemical Information, Storage & Stability

Molecular Weight	187.19	Formula	C₁₀H₁₁O₂.Na	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	1716-12-7	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	4-Phenylbutyric acid, NaPB			Smiles	C1=CC=C(C=C1)CCCC(=O)[O-].[Na+]

Solubility

In vitro
Batch:

DMSO : 37 mg/mL (197.66 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : 37 mg/mL

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	1.850mg/ml (9.88mM)	Taking the 1 mL working solution as an example, add 50 μL of 37 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC₅₀/Ki	HDAC ^[1]
In vitro	4-PBA (Sodium Phenylbutyrate) is a well-known HDAC inhibitor, which increases gene transcription of a number of genes, and also exerts neuroprotective effects. It significantly attenuates MPTP-induced depletion of striatal dopamine and loss of tyrosine hydroxylase-positive neurons in the substantia nigra. ^[1] This compound also attenuates the expression of the apoptosis antagonist Bcl-X(L), the double-strand break repair protein DNA-dependent protein kinase, the prostate progression marker caveolin-1, and the pro-angiogenic vascular endothelial growth factor in prostate cancer cells. It is found to act in synergy with ionizing radiation to induce apoptosis in prostate cancer cells. ^[2]
In vivo	4-PBA (Sodium Phenylbutyrate) significantly extends survival and improved both the clinical and neuropathological phenotypes in G93A transgenic ALS mice. This compound ameliorates histone hypoacetylation observed in G93A mice and induced expression of nuclear factor-kappaB (NF-kappaB) p50, the phosphorylated inhibitory subunit of NF-kappaB (pIkappaB) and beta cell lymphoma 2 (bcl-2), but reduced cytochrome c and caspase expression. It acts to phosphorylate IkappaB, translocating NF-kappaB p50 to the nucleus, or to directly acetylate NF-kappaB p50. ^[3] It also increases brain histone acetylation and decreased histone methylation levels as assessed by both immunocytochemistry and Western blots in a transgenic mousemodel of Huntington's disease (HD). The compound increases mRNA for components of the ubiquitin-proteosomal pathway and down-regulated caspases implicated in apoptotic cell death, and active caspase 3 immunoreactivity in the striatum. ^[4]
References	[1] https://pubmed.ncbi.nlm.nih.gov/15626823/ [2] https://pubmed.ncbi.nlm.nih.gov/11571633/ [3] https://pubmed.ncbi.nlm.nih.gov/15934930/ [4] https://pubmed.ncbi.nlm.nih.gov/15494404/ [5] https://pubmed.ncbi.nlm.nih.gov/34716302/ [6] https://pubmed.ncbi.nlm.nih.gov/28649223/

Applications

Methods	Biomarkers	Images	PMID
Western blot	Survivin p38 / p-p38 / ERK / p-ERK / JNK / p-JNK		27274278

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT05983588	Recruiting	Corticobasal Syndrome (CBS)	Technical University of Munich	December 12 2023	Phase 2
NCT05019417	Unknown status	Monocarboxylate Transporter 8 Deficiency	Kaplan Medical Center\|Weizmann Institute of Science	June 30 2021	Phase 2\|Phase 3
NCT04937062	Enrolling by invitation	STXBP1 Encephalopathy With Epilepsy SLC6A1 Neurodevelopmental Disorder\|Developmental and Epileptic Encephalopathy	Weill Medical College of Cornell University\|Children''s Hospital Colorado\|SLC6A1 Connect\|STXBP1 Foundation\|Clara Inspired\|University of Pennsylvania Orphan Disease Center\|Horizon Therapeutics	March 1 2021	Early Phase 1
NCT04421677	Completed	Inclusion Body Myositis\|Sporadic Inclusion Body Myositis	University of Kansas Medical Center	August 20 2020	Phase 1
NCT02246218	Completed	Urea Cycle Disorder	Horizon Therapeutics LLC\|Horizon Pharma Ireland Ltd. Dublin Ireland	December 31 2014	Phase 4
NCT01096095	Withdrawn	Spinocerebellar Ataxia Type 3	Hospital de Clinicas de Porto Alegre\|Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul Brazil	June 2010	Phase 2

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):